On October 1, Abivax S.A. fell 5.18% in regular trading, trading at 93.94 USD/share, with turnover of approximately $29.83 million. The decline reflects sustained pressure from a recent earnings miss compounded by multiple analyst downgrades.

Abivax reported quarterly results on September 21 that fell short of expectations, with EPS coming in at -$1.71. In the wake of the report, Wedbush cut its price target from $160 to $118 with a Neutral rating, while Truist trimmed its target from $155 to $151 but maintained a Buy rating. Most notably, Wall Street Zen downgraded the stock from Hold to Sell on September 26, adding further selling pressure. This string of negative revisions contrasts with more bullish stances from Goldman Sachs, which initiated coverage at Buy with a $155 target, and Morgan Stanley, which reiterated Overweight with a $180 target.

Abivax S.A. is a clinical-stage biotechnology company developing obefazimod, currently in Phase 3 trials for moderately to severely active ulcerative colitis. The company plans to submit a new drug application by year-end, supported by a roughly EUR 767 million equity raise extending its cash runway into Q4 of the following fiscal year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)